# Einstein Mount Sinai Diabetes Research Center

> **NIH NIH P30** · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2021 · $147,924

## Abstract

Over the past decade, a succession of remarkable technological advances has reconfigured the landscape of
biomedical research using “immuno-technologies”, the broad collection of methodologies pertaining to the
quantification, correlation and visualization of analytical modalities in the study of the immune system. Despite
their extraordinary promise, however, implementation of these technologies by academic researchers includes
significant obstacles, chiefly the need for ready access to appropriate technological infrastructure and the
considerable cost associated with assay performance. To address these challenges, the new Immuno-
Technology Core (ITC) has been conceived as an education, coordination and service core that will provide a
paradigm for inter-institutional cooperation and will be the focus of directed recruitment and expansion of
our diabetes immunology research base. Specifically, the ITC will focus its activities on distinct technology
platforms that have been prioritized in discussion with multiple Einstein-Mount Sinai Diabetes Research Center
(ES-DRC) investigators, based on the evolving research needs of our research base. Access to respective
services is distributed across both Einstein and Mount Sinai; the ITC will harness the combined technology
infrastructure for the following objectives:
1. To raise awareness about select state-of-the-art technology infrastructure available at Einstein and Mount
 Sinai (cellular, imaging, and immunomodulation platforms); to provide consultation and advice about the
 potential and limitations of respective technologies; to assist investigators with experimental planning,
 design and considerations about expected financial investments; and to facilitate interactions with
 managers, application scientists and data analysis specialists working with each technology platform.
2. To provide support services required for the effective and efficient implementation of tailored experimental
 protocols. Accordingly, the ITC will focus on specific reagent selection, testing and validation; protocol
 adjustment and optimization; and integration with established assay workflows.
3. To facilitate access and provide practical support for the usage of selected technology platforms: a)
 cellular – mass cytometry / Cytometry by Time-of-Flight (CyTOF); b) imaging – multiplexed
 immunohistochemistry and whole-slide imaging as well as biophotonic in vivo imaging; and c)
 immunomodulation – synTac technology developed at Einstein for antigen-specific T cell modulation.
Collectively, ITC services and expertise will support and advance the work of ES-DRC investigators by
catalyzing the integration of cutting-edge, complex and otherwise often cost-prohibitive technologies into
their research programs. Conceived as a novel and unique resource for the study of both islet biology and
the immunological aspects of type 1 and type 2 diabetes and obesity, the ITC will both support existing
ES-DRC efforts and serve as a rec...

## Key facts

- **NIH application ID:** 10130499
- **Project number:** 5P30DK020541-46
- **Recipient organization:** ALBERT EINSTEIN COLLEGE OF MEDICINE
- **Principal Investigator:** Teresa P DiLorenzo
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $147,924
- **Award type:** 5
- **Project period:** 1996-12-01 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10130499

## Citation

> US National Institutes of Health, RePORTER application 10130499, Einstein Mount Sinai Diabetes Research Center (5P30DK020541-46). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10130499. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*